Drug
S 892216 Lai
S 892216 Lai: highest development phase Phase 1, developed by Shionogi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| S-892216-LAI NCT07093580 | Phase 1 |
Latest
No recent events.
Follow S 892216 Lai on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.